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Patients with a moderately reduced glomerular filtration rate
(GFR) typically have no metabolic acidosis and a urine net
acid excretion comparable to those with normal GFR,
supporting greater per nephron acidification with
moderately reduced GFR. We modeled such patients using
rats with a surgical reduction of 2/3 kidney mass, yielding
animals with reduced GFR without metabolic acidosis. We
then tested the hypothesis that reduction of nephron mass
augments distal nephron acidification in remnant nephrons
mediated by increased angiotensin II activity, and that the
latter is induced by underlying acid retention. Nephron mass
reduction yielded lower GFR than controls (sham operation),
higher acid retention (measured by microdialysis of kidney
cortex), higher distal nephron acidification, and higher
plasma and kidney levels of angiotensin II, but plasma total
CO2 and urine net acid excretion were not different.
Angiotensin II receptor antagonism reduced distal nephron
acidification to levels similar to control. Dietary alkali that
lowered acid retention to that of control also reduced plasma
and kidney levels of angiotensin II and reduced distal
nephron acidification to control. Angiotensin II receptor
antagonism with dietary alkali had no significant added
effect on distal nephron acidification. Thus, nephron
reduction that moderately reduced GFR with no metabolic
acidosis is characterized by increased angiotensin II activity.
This mediates increased distal nephron acidification and is
induced by acid retention.
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The metabolic acidosis of chronic kidney disease (CKD)
typically occurs in patients with very low glomerular
filtration rate (GFR),1 and its treatment with alkali appears
to slow nephropathy progression.2,3 Even so, lower levels of
serum HCO3 within the normal range are associated with
faster nephropathy progression in subjects with reduced
GFR,4 and oral NaHCO3 slows nephropathy progression in
patients with GFR that is reduced but not to levels associated
with metabolic acidosis.5 Patients with reduced GFR
commonly do not have metabolic acidosis5,6 and often have
urine net acid excretion (NAE) that is comparable to those
with normal GFR.7–9 These patients presumably have
increased per nephron acidification, but this hypothesis
cannot be tested directly in humans. Animal models of CKD
support those substances that help increase kidney acidifica-
tion in animals with very low GFR, and metabolic
acidosis10–12 might also contribute to nephropathy progres-
sion.13 Animals with the classic 5/6 nephrectomy (Nx) model
of CKD have increased distal nephron acidification10–13 with
metabolic acidosis.12 By contrast, animals with 2/3 Nx have
better-preserved GFR without metabolic acidosis, yet have
progressive GFR decline.14,15 These 2/3 Nx animals model
patients with reduced but better-preserved GFR, many of
whom have progressive GFR decline despite kidney-protec-
tive interventions,3,5,16 and comprise the largest cadre of
patients with CKD.17 Consequently, patients with reduced
GFR without metabolic acidosis might have increased kidney
acidification that is maintained by substances that mediate
progressive GFR decline. The 2/3 Nx model can help
determine whether increased distal nephron acidification
accompanies reduced GFR without metabolic acidosis, and if
so, whether increased acidification is mediated by substances
that have been associated with nephropathy progression.
Progressive GFR decline in 5/6 Nx animals is mediated
through angiotensin II (AII) receptors,18 but AII also
increases distal nephron acidification in 5/6 Nx animals10,11
and might do so in 2/3 Nx animals. Supporting this
hypothesis, chronic dietary acid (Hþ ) in animals with
intact nephron mass that causes Hþ retention19 but no
metabolic acidosis19,20 activates the kidney renin–angiotensin
system, including the expression of AII type 1 receptors.20
Animals with 2/3 Nx also have Hþ retention that mediates
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progressive GFR decline,14,15 and might have increased
kidney AII that in turn increases distal nephron acidification.
In addition, AII increases kidney endothelin-1 (ET-1)21 and
the ETs mediate increased distal nephron acidification in 5/6
Nx animals.12 In addition, AII increases kidney aldosterone
(Aldo),22 which mediates increased distal nephron acidifica-
tion in response to dietary Hþ .23 If kidney AII is increased by
Hþ retention, it might mediate the increased kidney levels of
ET-1 and Aldo induced by Hþ retention in 2/3 Nx animals.15
The present studies tested the hypothesis that 2/3 Nx animals
without metabolic acidosis have augmented distal nephron
acidification that is induced by Hþ retention and mediated
through AII, ET, and Aldo receptors.
RESULTS
GFR, acid–base parameters, and levels of AII, ET-1, and Aldo
Although 2/3 Nx animals (hereafter ‘Nx’) had lower GFR
than Sham animals (2615±174 vs. 4217±336 ml/min,
Po0.001), Table 1 shows no difference in arterial plasma
total CO2 (TCO2), pH, PCO2, [K
þ ], or urine NAE and its
components between conscious Nx and Sham animals.
Although total urine NAE was not different between Nx
and Sham animals, fractional acid excretion was higher in Nx
animals (19.25±2.4 vs. 13.08±1.44, Po0.01). Table 1 shows
that Nx had higher-than-Sham plasma levels of AII, ET-1,
and Aldo. Despite no difference in plasma acid–base
parameters and urine NAE, Nx had higher-than-Sham kidney
cortical microdialysate addition of Hþ , AII, ET-1, and Aldo.
Although overall urine NAE was not different between Nx
and Sham animals, Nx animals had lower urine excretion of
ammonium (NH4
þ ) and HCO3.
Distal nephron acidification in Nx and Sham animals
Figure 1 shows that Nx animals had higher-than-Sham distal
nephron net HCO3 reabsorption (JHCO3) perfused at 6 nl/min
(23.3±1.9 vs. 11.2±1.4 pmol/mmmin, Po0.001), the in situ
flow rate of Sham, and at 9 nl/min (33.4±3.5 vs. 15.4±
1.3 pmol/mmmin, Po0.001), the in situ flow rate of Nx.
Hþ transport mediators of greater distal nephron
acidification in Nx
Table 2 shows that the ethylisopropylamiloride (EIPA)-
sensitive, bafilomycin-sensitive, and Schering 28080–sensitive
decrease in distal nephron net JHCO3 was significantly greater
in Nx compared with Sham animals in distal nephrons perfused
at 6 or 9 nl/min, supporting the hypothesis that increased
Naþ /Hþ , Hþ -ATPase, and possibly Hþ , Kþ -ATPase
activity, respectively, mediated augmented Nx net JHCO3.
Contributions of AII, ET, and Aldo to greater Nx distal
nephron JHCO3: effect of chronic oral receptor antagonists
Figure 2 shows lower-than-baseline net JHCO3 in Sham
animals (upper panel) given all three receptor antagonists
(8.5±1.1 vs. 11.4±0.9 pmol/mmmin, Po0.001), but an-
tagonist compared with baseline net JHCO3 was not different
in Sham animals given valsartan (11.2±1.3 vs.
11.8±1.4 pmol/mmmin, P¼ 0.366), bosentan (11.0±1.1
vs. 11.4±0.8 pmol/mmmin, P¼ 0.471), or eplerenone
(11.7±1.5 vs. 12.0±1.2 pmol/mmmin, P¼ 0.719) alone.
By contrast, antagonist compared with baseline net JHCO3 was
lower in Nx animals (lower panel) given valsartan (11.9±1.4
vs. 33.1±1.9 pmol/mmmin, Po0.001), bosentan (17.5±2.0
vs. 33.9±1.3 pmol/mmmin, Po0.001), eplerenone
(24.8±1.6 vs. 32.8±1.9 pmol/mmmin, Po0.001), and all
three antagonists (8.1±1.0 vs. 33.2±2.7 pmol/mmmin,
Po0.001) perfused at 9 nl/min. The data support the
hypothesis that Sham baseline net JHCO3 for distal nephrons
perfused at its in situ rate of 6 nl/min is not dependent
individually upon AII, ET, or Aldo. The data also support the
Table 1 | Laboratory values for Sham vs. Nx (n=8 animals for
each group)
Sham Nx P-value
Arterial plasma TCO2 (mmol/l) 25.0±0.7 24.7±1.3 0.6563
Arterial pH 7.404±0.006 7.401±0.004 0.2020
Arterial PCO2 (mmHg) 39.5±0.8 39.0±0.8 0.2893
Arterial K+ (meq/l) 4.0±0.1 4.0±0.1 0.5625
Urine NAE (mmol/l/day) 3.09±0.32 2.86±0.31 0.1547
Urine NH4
+ (mmol/l/day) 1.68±0.20 1.49±0.09 0.0279
Urine TA (meq/day) 1.50±0.23 1.39±0.26 0.3726
Urine HCO3 (mmol/l/day) 0.09±0.02 0.02±0.01 o0.0001
Plasma AII (fm/ml) 89.1±22.3 127.9±29.2 0.0098
Plasma ET-1 (fm/ml) 4.1±1.0 6.4±1.2 0.0007
Plasma Aldo (fm/ml) 499.4±149.9 1004.9±255.4 0.0003
Microdialysate net H+
addition (fm/ml)
48.0±26.2 632.3±203.4 o0.0001
Microdialysate net AII
addition (fm/ml)
85.6±32.6 141.4±44.2 0.0123
Microdialysate net ET-1
addition (fm/ml)
354.8±84.2 1210.3±345.6 o0.0001
Microdialysate net Aldo
addition (fm/ml)
81.1±25.1 396.1±154.0 0.0001
Abbreviations: AII, angiotensin II; Aldo, aldosterone; ET-1, endothelin-1; micro-
dialysate, effluent microdialysate from microdialysis of the kidney cortex; NAE, net
acid excretion; Nx, 2/3 nephrectomy; Sham, sham-operated animals; TCO2, total CO2;
urine HCO3, urine HCO3 excretion; urine NH4
+, urine ammonium excretion; urine TA,
urine titratable acid excretion.
Values are means±s.d.
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Figure 1 |Distal nephron net HCO3 reabsorption (JHCO3) (pmol/
mmmin) in epithelia of Nx and Sham perfused at 6 and 9nl/
min. The bottom and top of the boxes span the 25th and 75th
percentile of data points. The dark bar within the box indicates
the 50th percentile or median. The whiskers indicate 1.5 times the
interquartile range for the lower and upper quartiles. *Po0.05; Nx
vs. respective Sham.
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hypothesis that AII, ET, and Aldo individually contribute to
increased net JHCO3 in Nx, but that AII makes the greatest
quantitative contribution.
AII, ET, and Aldo influence on Hþ transporters of distal
nephron JHCO3: effect of chronic oral receptor antagonists
Table 3 shows in Sham animals perfused at 6 nl/min, the
EIPA-sensitive decrease in net JHCO3 was lower in valsartan-
treated and three-drug-treated Shams compared with base-
line, consistent with AII-mediated distal nephron Naþ /Hþ
exchange in Sham animals at baseline. There was no
difference in the EIPA-sensitive decrease in JHCO3 in
bosentan-treated and eplerenone-treated Shams, consistent
with no ET-mediated or Aldo-mediated Naþ /Hþ exchange
in Sham animals at baseline. The bafilomycin-sensitive and
Schering 28080–sensitive decrease in net JHCO3 in Sham
animals was not lower in antagonist-treated animals
compared with the respective baseline animals, consistent
with no ET-mediated and no Aldo-mediated Hþ -ATPase or
Hþ , Kþ -ATPase activity under baseline conditions in Sham
animals. By contrast, Table 3 shows in Nx that the EIPA-
sensitive and bafilomycin-sensitive decrease in JHCO3 was
lower in individual antagonist-treated and three-drug-treated
Nx animals than baseline, supporting the hypothesis that
increased Naþ /Hþ and Hþ -ATPase activity in Nx animals is
mediated by AII, ETs, Aldo, or their combination. Schering
28080–sensitive JHCO3 was lower than baseline with the three
antagonists combined, but was not different with each
antagonist administered individually. These latter data are
consistent with no effect of AII, ET, or Aldo individually on
Hþ , Kþ -ATPase in Nx at baseline, but simultaneous
antagonism of each of their receptors modestly reduced the
Hþ , Kþ -ATPase activity.
Figure 3 shows the effect of the individual antagonists or
their combination on net JHCO3 in Nx compared with Sham
animals when their distal nephrons were perfused at the same
9 nl/min rate. Net JHCO3 was not different between Nx and
Sham animals when each received valsartan (11.7±1.7 vs.
11.2±1.3 pmol/mmmin, respectively, P¼ 0.538) or all three
antagonists (8.1±1.0 vs. 8.7±0.6 pmol/mmmin, respectively,
P¼ 0.210). The data show that non-AII-mediated net JHCO3
was not different between Nx and Sham animals, and support
an important AII role in mediating higher net JHCO3 in Nx
compared with Sham animals. By contrast, net JHCO3 was
higher in Nx than Sham animals when each received bosentan
(16.7±1.7 vs. 10.2±1.2 pmol/mmmin, respectively, Po0.001)
or eplerenone (25.2±1.3 vs. 13.1±1.1 pmol/mmmin, re-
spectively, Po0.001). These data support the hypothesis that
non-ET-mediated and non-Aldo-mediated net JHCO3 were
higher in Nx than Sham animals, supporting the hypothesis
that endothelin and aldosterone individually contributed to
the increment in net JHCO3 between Nx and Sham, but did so
quantitatively less than the AII-mediated JHCO3.
Table 2 | Net decrease in JHCO3 induced by EIPA, bafilomycin, and Schering 28080 by group (Sham vs. Nx) at perfusion rates
6 and 9nl/min (n=8 animals with one tubule per flow rate per animal)
6nl/min 9 nl/min
EIPA (pmol/
mmmin)
Bafilomycin (pmol/
mmmin)
Schering 28080 (pmol/
mmmin)
EIPA (pmol/
mmmin)
Bafilomycin (pmol/
mmmin)
Schering 28080 (pmol/
mmmin)
Sham 6.1±0.8 3.0±0.4 2.0±0.5 9.0±1.0 4.4±0.5 3.2±0.5
Nx 11.5±1.0* 9.5±1.0* 2.9±0.6* 16.8±1.8* 13.8±2.0* 3.9±0.6*
Abbreviations: EIPA, ethylisopropylamiloride; JHCO3, distal nephron net HCO3 reabsorption; Nx, 2/3 nephrectomy.
Values are means±s.e. Losartan is the angiotensin II receptor antagonist; bosentan is the endothelin A/B receptor antagonist; eplerenone is the mineralocorticoid receptor
antagonist. All animals ingested diets containing 20% casein as protein. *Po0.05 vs. respective index value.
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Figure 2 |Distal nephron net HCO3 reabsorption (JHCO3) in
Sham (upper panel) and Nx (lower panel) animals in response
to chronic oral administration of the individual receptor
antagonists and in animals given all three receptor
antagonists. (a) Sham (6 nl/min) and (b) Nx (9 nl/min). *Po0.05
vs. respective baseline. Open circles near boxplots indicate data
points outside of 1.5 times the interquartile range for lower or
upper quartiles.
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Table 4 shows Hþ -transporter inhibitor–sensitive decreases
JHCO3 in Nx compared to Sham when each were treated with
the three receptor antagonists individually or altogether and
their distal nephrons were each perfused at 9 nl/min. The
EIPA-sensitive and bafilomycin-sensitive decrease in JHCO3
was greater in Nx than Sham animals treated with
eplerenone but not in those treated with the remaining
antagonists, consistent with non-Aldo-mediated Naþ /Hþ
exchange and non-Aldo-mediated Hþ -ATPase activity
contributing to greater overall net JHCO3 in Nx than Sham
animals.
As the data support contributions of AII, ET, and Aldo to
increased net JHCO3 in Nx than Sham animals but a
disproportionately greater role for AII, Table 5 compares
the levels of various parameters in valsartan-treated and
baseline Nx and Sham animals. Plasma TCO2, pH, and PCO2
were lower and plasma [Kþ ] was higher in valsartan-treated
than baseline Nx animals, but not in Sham animals. Overall
urine NAE was not different between valsartan-treated and
baseline Nx animals, but valsartan-treated Nx animals had
lower urine NH4
þ excretion. Microdialysate net Hþ addition
was not different between valsartan-treated and baseline for
both Nx and Sham animals. Plasma AII and kidney
microdialysate AII addition were higher in valsartan-treated
animals compared with baseline for both Nx and Sham
animals as expected in response to this AII receptor
antagonist. By contrast, ET-1 plasma concentration and
microdialysate addition, as well as Aldo plasma concentration
and microdialysate addition, were lower than baseline in the
valsartan-treated Nx animals. Sham animals treated with
valsartan had lower plasma Aldo and lower Aldo micro-
dialysate addition than baseline, but these respective values
for ET-1 were not different.
Effect of reducing Hþ microdialysate addition of Nx to Sham
levels with dietary alkali
Table 6 shows that Nx animals given calcium bicarbonate
(CaHCO3) in amounts that lowered Nx dialysate H
þ
addition to Sham levels (Methods) and those given calcium
gluconate (CaGlu) that provided Caþ þ without alkali had
plasma TCO2 that was not different among the three groups.
Compared with Nx, however, Nx given CaHCO3 but not
CaGlu had lower urine NAE mediated by lower urine
excretion of NH4
þ and titratable acidity and by higher urine
HCO3 excretion. In addition, Nx animals given CaHCO3 but
Table 3 | Net decrease in JHCO3 induced by EIPA, bafilomycin, and Schering 28080 by drugs within groups (n=8 animals with
one tubule per flow rate per animal)
Sham=6nl/min Nx=9nl/min
Strata Drug
EIPA
(pmol/mmmin)
Bafilomycin
(pmol/mmmin)
Schering 28080
(pmol/mmmin)
EIPA
(pmol/mmmin)
Bafilomycin
(pmol/mmmin)
Schering 28080
(pmol/mmmin)
1 Baseline 5.6±0.7 3.2±0.5 2.4±0.5 16.4±1.0 13.5±1.9 3.4±1.0
Valsartan 4.4±0.4* 3.2±0.6 3.2±0.7* 4.8±0.6* 3.3±0.5* 3.2±0.5
2 Baseline 5.4±1.0 4.4±0.6 2.2±0.4 16.6±1.2 14.5±1.6 3.3±0.7
Bosentan 5.6±0.7 4.3±0.6 2.5±0.3 8.2±1.0* 5.7±0.8* 3.5±0.4
3 Baseline 4.8±0.7 4.5±0.9 2.3±0.3 16.2±1.5 13.1±1.6 3.2±0.8
Eplerenone 4.3±0.8 4.5±0.7 2.2±0.4 14.9±1.6 6.3±0.8* 3.2±0.4
4 Baseline 4.5±0.4 4.2±0.6 2.3±0.3 16.1±1.3 13.1±1.6 3.6±0.5
3 Drugs 3.8±0.3* 3.0±0.4* 2.4±0.5 3.1±0.4* 1.9±0.4* 3.0±0.4*
Abbreviations: EIPA, ethylisopropylamiloride; JHCO3, distal nephron net HCO3 reabsorption; Nx, 2/3 nephrectomy.
*Po0.05 vs. respective baseline.
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Figure 3 |Distal nephron net HCO3 reabsorption (JHCO3)
between Nx vs. Sham when each was treated with the three
receptor antagonists individually or with all three together.
*Po0.05 vs. respective Sham.
Table 4 | Net decrease in JHCO3 induced by EIPA, bafilomycin,
and Schering 28080 for groups at 9 nl/min (n=8 animals with
one tubule per animal)
Drug Group
EIPA (pmol/
mmmin)
Bafilomycin
(pmol/mmmin)
Schering 28080
(pmol/mmmin)
Valsartan Sham 4.4±0.4 3.2±0.6 3.2±0.7
Nx 4.7±0.8 3.5±0.7 3.3±0.4
Bosentan Sham 6.6±1.0 5.5±0.8 2.9±0.4
Nx 8.1±1.9 5.7±1.1 3.2±0.8
Eplerenone Sham 8.3±0.8 4.7±0.7 2.8±0.4
Nx 14.8±1.0* 6.1±0.8* 3.3±0.5
3 Drugs Sham 3.5±0.4 2.1±0.4 2.5±0.4
Nx 3.1±0.4 1.9±0.4 3.0±0.4
Abbreviations: EIPA, ethylisopropylamiloride; JHCO3, distal nephron net HCO3
reabsorption; Nx, 2/3 nephrectomy.
*Po0.05 vs. Sham.
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not CaGlu had lower plasma concentrations and lower
microdialysate addition of AII, ET-1, and Aldo. Figure 4
shows that NxþCaHCO3 (13.0±1.1 pmol/mmmin) but not
NxþCaGlu (32.6±2.2 pmol/mmmin) animals had lower net
JHCO3 than Nx animals (32.8±2.1 pmol/mmmin, Po0.001
vs. NxþCaHCO3) when their distal nephron epithelia were
perfused at 9 nl/min. Table 7 shows that the Hþ -transporter
inhibitor–sensitive decrease in net JHCO3 was lower in Nxþ
CaHCO3 compared with Nx animals with EIPA (Po0.001),
bafilomycin (Po0.001), and Schering 28080 (Po0.001), con-
sistent with lower Naþ /Hþ , lower Hþ -ATPase, and lower Hþ ,
Kþ -ATPase activity, respectively, in NxþCaHCO3 compared
with Nx animals.
As dietary alkali and valsartan each reduced JHCO3 in Nx
animals to levels comparable to that of Sham animals, Figure 5
compares NxþCaHCO3 with NxþCaHCO3þ valsartan Nx
Table 5 | Lab values for baseline vs. valsartan within groups (n=8 animals in each group)
Sham Nx
Baseline Valsartan P-value Baseline Valsartan P-value
Arterial TCO2 (mmol/l) 24.8±0.6 25.0±0.2 0.2447 24.6±0.7 23.3±0.6 0.0012
Arterial pH 7.403±0.007 7.401±0.005 0.6674 7.401±0.007 7.388±0.006 0.0011
Arterial PCO2 (mmHg) 39.7±0.6 39.8±0.6 0.5474 38.9±0.5 37.5±0.4 o0.0001
Arterial K+ (meq/l) 3.94±0.13 4.01±0.15 0.2962 3.98±0.10 4.14±0.12 0.0113
Urine NAE (mmol/l/day) 3.1±0.2 3.0±0.2 0.2434 2.9±0.2 2.6±0.2 0.0503
Urine NH4
+ (mmol/l/day) 1.70±0.12 1.63±0.12 0.2504 1.46±0.12 1.28±0.10 0.0056
Urine TA (meq/day) 1.54±0.10 1.51±0.09 0.5377 1.42±0.11 1.35±0.15 0.3305
Urine HCO3 (mmol/l/day) 0.12±0.04 0.13±0.04 0.8662 0.02±0.02 0.02±0.01 0.5373
Plasma AII (fm/ml) 90.0±21.2 126.4±15.8 0.0016 126.4±21.5 165.4±22.5 0.0032
Plasma ET-1 (fm/ml) 4.1±0.4 3.7±0.6 0.1465 6.8±1.1 5.7±0.5 0.0214
Plasma Aldo (fm/ml) 499.6±72.4 421.6±55.5 0.0298 1008.8±151.5 845.9±143.5 0.0445
Net H+ addition (fm/ml) 29.9±16.8 26.8±27.7 0.7891 655.3±103.2 721.4±134.5 0.2885
Net AII addition (fm/ml) 88.3±14.8 148.3±16.6 o0.0001 143.5±32.0 314.5±68.9 o0.0001
Net ET-1 addition (fm/ml) 383.5±63.5 386.3±56.2 0.9282 1217.8±194.3 591.1±119.2 o0.0001
Net Aldo addition (fm/ml) 85.0±20.1 65.1±11.1 0.0278 398.6±76.7 227.0±70.5 0.0004
Abbreviations: AII, angiotensin II; Aldo, aldosterone; ET-1, endothelin-1; microdialysate, effluent microdialysate from microdialysis of the kidney cortex; NAE, net acid excretion;
Nx, 2/3 nephrectomy; Sham, sham-operated animals; TCO2, total CO2; urine HCO3, urine HCO3 excretion; urine NH4
+, urine ammonium excretion; urine TA, urine titratable acid
excretion.
Values are means±s.d.
Table 6 | Lab values for Nx vs. Nx+drug (n=8 animals for each group)
Baseline CaHCO3 Ca Glu
Baseline vs.
CaHCO3
Baseline vs.
Ca Glu
CaHCO3 vs.
Ca Glu
Arterial TCO2 (mmol/l) 25.0±0.4 25.0±0.3 25.1±0.2 0.8181 0.4462 0.3243
Arterial pH 7.402±0.005 7.399±0.006 7.405±0.005 0.2852 0.3262 0.0478
Arterial PCO2 (mmHg) 39.1±0.6 39.5±0.5 39.1±0.5 0.1606 0.8529 0.1155
Arterial K+ (meq/l) 3.93±0.10 3.91±0.10 3.95±0.12 0.8187 0.6474 0.4940
Urine NAE (mmol/l/day) 3.08±0.16 1.09±0.13 3.06±0.18 o0.0001 0.8145 o0.0001
Urine NH4
+ (mmol/l/day) 1.48±0.08 0.49±0.09 1.46±0.11 o0.0001 0.7898 o0.0001
Urine TA (meq/day) 1.62±0.09 0.80±0.03 1.78±0.13 o0.0001 0.0023 o0.0001
Urine HCO3 (mmol/l/day) 0.02±0.02 0.20±0.05 0.02±0.01 o0.0001 0.8733 o0.0001
Plasma AII (fm/ml) 125.4±18.1 75.1±10.5 125.5±11.3 o0.0001 0.9856 o0.0001
Plasma ET-1 (fm/ml) 6.4±0.9 4.0±0.3 6.3±0.7 o0.0001 0.7801 o0.0001
Plasma Aldo (fm/ml) 1029.1±127.4 486.6±55.1 1050.6±133.6 o0.0001 0.7029 o0.0001
Net H+ addition (fm/ml) 644.1±83.2 7.1±29.8 634.9±79.1 o0.0001 0.7896 o0.0001
Net AII addition (fm/ml) 148.5±16.5 57.1±19.3 143.3±19.1 o0.0001 0.5730 o0.0001
Net ET-1 addition (fm/ml) 1140.4±250.4 440.3±99.1 1124.5±172.1 o0.0001 0.8650 o0.0001
Net Aldo addition (fm/ml) 394.8±98.7 210.8±48.8 389.0±50.4 o0.0001 0.8709 o0.0001
Abbreviations: AII, angiotensin II; Aldo, aldosterone; ET-1, endothelin-1; microdialysate, effluent microdialysate from microdialysis of the kidney cortex; NAE, net acid excretion;
Nx, 2/3 nephrectomy; Sham, sham-operated animals; TCO2, total CO2; urine HCO3, urine HCO3 excretion; urine NH4
+, urine ammonium excretion; urine TA, urine titratable acid
excretion.
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Figure 4 |Distal nephron net HCO3 reabsorption (JHCO3) in Nx,
Nxþdietary alkali (CaHCO3), and Nx given dietary Caþ þ
without alkali (Caþ þ gluconate¼CaGlu) in distal nephron
epithelia perfused at 9 nl/min. *Po0.05 vs. Nx; þPo0.05 vs.
NxþCaGlu.
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to determine whether valsartan additionally reduced net JHCO3
in Nx animals given CaHCO3. The figure shows no
difference in JHCO3 between NxþCaHCO3 and NxþCaH-
CO3þ valsartan (12.5±0.9 vs. 12.1±0.8 pmol/mmmin,
respectively, P¼ 0.288). Table 8 shows no differences
in Hþ -transporter inhibitor–sensitive net JHCO3 decrease
between the two groups. The data support the hypothesis
that dietary alkali and valsartan reduced distal nephron
JHCO3 through the same acidification effectors. Table 9
compares levels of various parameters in NxþCaHCO3 vs.
NxþCaHCO3þ valsartan. Plasma TCO2, pH, PCO2, [Kþ ],
urine NAE and its components, and microdialysate net
Hþ addition were not different. Plasma AII and kidney
microdialysis AII addition were higher in valsartan-treated
Nx animals given dietary alkali. Microdialysate addition of
ET-1 but not Aldo was lower in NxþCaHCO3þ valsartan
than NxþCaHCO3.
DISCUSSION
Kidneys of subjects with chronically reduced GFR, such as Nx
animals, must increase per nephron Hþ excretion if they are
to avoid progressive Hþ accumulation when they are fed
diets of the same type and amount as those with intact nephron
mass.5,7,9 Humans with chronically reduced GFR can achieve
Hþ excretion equivalent to intrinsic Hþ production24 and
commonly do so without metabolic acidosis.6 These data
suggest that such patients have increased per nephron
acidification. The 2/3 Nx model used in previous14,15 and
present studies has reduced GFR and maintains urine NAE
comparable to Sham while ingesting the same amount and
type of diet, yet has no metabolic acidosis. Consequently, 2/3
Nx models the large cadre of CKD patients whose GFR is
reduced but not low enough to be associated with metabolic
acidosis.1 The present studies show that 2/3 Nx animals have
increased distal nephron acidification that is induced by Hþ
retention and mediated through AII receptors.
The GFR of 2/3 Nx animals was 62% of Sham and was
sufficient to avoid metabolic acidosis. How this level of
remaining GFR relates to that needed by humans to avoid
metabolic acidosis is an important question that was not
directly answered by these studies. Animals with 5/6 Nx and
metabolic acidosis had GFR that was 23% of Sham.13 We
suspect that factors other than the level of remaining GFR,
such as the acid content of their diets, contribute to whether
metabolic acidosis in humans with reduced GFR is present.
Nevertheless, humans who presumably consumed acid-
inducing diets typical of industrialized societies25 had
reduced serum [HCO3] when GFR was o20ml/min.1
Subjects selected to have plasma TCO2o22mmol/l from
those with estimated GFR (eGFR)420 but o60ml/min had
mean eGFR¼ 33ml/min.3 Other studies selecting subjects
with plasma TCO2424mmol/l from those with eGFRX60
but o90ml/min had mean eGFR¼ 75ml/min.5 We suggest
Table 7 | Reductions in net JHCO3 induced by EIPA,
bafilomycin, and Schering 28080 in Nx animals given Ca Glu
and CaHCO3 compared with baseline (n=8 animals with one
tubule per animal)
Drug
EIPA
(pmol/mmmin)
Bafilomycin
(pmol/mmmin)
Schering 28080
(pmol/mmmin)
Baseline 14.0±0.8 12.2±1.5 3.1±0.5
CaHCO3 7.9±0.8* 4.7±0.5* 1.4±0.3*
Ca Glu 13.6±1.5+ 12.0±0.9+ 3.2±0.5+
Abbreviations: EIPA, ethylisopropylamiloride; JHCO3, distal nephron net HCO3
reabsorption; Nx, 2/3 nephrectomy.
*P-value o0.05 vs. respective baseline; +P-value o0.05 for Ca Glu vs. CaHCO3.
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Figure 5 |Distal nephron net HCO3 reabsorption (JHCO3) in
Nxþdietary alkali (CaHCO3) and NxþCaHCO3þ valsartan in
distal nephron epithelia perfused at 9 nl/min.
Table 8 | Reductions in net JHCO3 induced by EIPA,
bafilomycin, and Schering 28080 for CaHCO3 compared with
CaHCO3+valsartan (n=8 animals with one tubule per animal)
Drug
EIPA (pmol/
mmmin)
Bafilomycin
(pmol/mmmin)
Schering 28080
(pmol/mmmin)
CaHCO3 7.5±0.5 4.7±0.6 1.4±0.3
CaHCO3+valsartan 7.4±0.7 4.3±0.4 1.3±0.3
Abbreviations: EIPA, ethylisopropylamiloride; JHCO3, distal nephron net HCO3
reabsorption.
Table 9 | Laboratory values for Nx+CaHCO3 vs.
NX+CaHCO3+valsartan (n=8 animals for each group)
CaHCO3 CaHCO3+valsartan P-value
Arterial TCO2 (mmol/l) 25.2±0.4 25.2±0.3 0.831
Arterial pH 7.403±0.005 7.402±0.006 0.8141
Arterial PCO2 (mmHg) 39.5±0.3 39.4±0.4 0.7207
Arterial K+ (meq/l) 3.9±0.2 4.1±0.1 0.0516
Urine NAE (mmol/l/day) 0.99±0.12 1.00±0.13 0.8459
Urine NH4
+ (mmol/l/day) 0.45±0.07 0.42±0.08 0.4508
Urine TA (meq/day) 0.75±0.13 0.76±0.08 0.9071
Urine HCO3 (mmol/l/day) 0.22±0.08 0.18±0.05 0.3116
Plasma AII (fm/ml) 77.6±7.4 90.8±11.9 0.019
Plasma ET-1 (fm/ml) 3.8±0.2 3.5±0.4 0.080
Plasma Aldo (fm/ml) 482.5±42.6 471.8±28.3 0.561
Net H+ addition (fm/ml) 2.6±21.4 9.0±20.4 0.552
Net AII addition (fm/ml) 73.5±14.0 97.3±24.0 0.030
Net ET-1 addition (fm/ml) 437.8±50.4 386.6±34.9 0.033
Net Aldo addition (fm/ml) 217.6±37.6 207.8±33.1 0.586
Abbreviations: AII, angiotensin II; Aldo, aldosterone; ET-1, endothelin-1; micro-
dialysate, effluent microdialysate from microdialysis of the kidney cortex; NAE, net
acid excretion; Nx, 2/3 nephrectomy; Sham, sham-operated animals; TCO2, total CO2;
urine HCO3, urine HCO3 excretion; urine NH4
+, urine ammonium excretion; urine TA,
urine titratable acid excretion.
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that the 2/3 Nx animal of the present studies models patients
with remaining GFR, that is 50–60% of normal, but further
studies will be needed to support or refute this assertion.
Although 2/3 Nx animals have no metabolic acidosis, these
and previous14,15 studies show that they have Hþ retention
even though their urine NAE was comparable to Sham when
each was fed the same type and diet amount. Reducing Hþ
retention in 2/3 Nx animals to Sham levels with dietary alkali
reduced augmented distal nephron acidification and also
reduced the associated increased plasma and kidney levels of
AII, ET-1, and Aldo. By contrast, AII, ET, and mineralocorti-
coid receptor antagonists reduced distal nephron acidification
without affecting Hþ retention. These data support the
hypothesis that Hþ retention in 2/3 Nx animals increases
plasma and kidney levels of ET-1 and Aldo as shown
previously,15 and increases kidney levels of AII as well. In
addition, these studies show that each of these three
substances augment distal nephron acidification, that AII
makes the greatest quantitative contribution of the three, and
support the hypothesis that AII increases urine NH4
þ
excretion as previously shown26 and contributes to increased
plasma and kidney levels of ET-1 and Aldo in 2/3 Nx animals.
How Hþ retention occurred and was sustained in 2/3 Nx
animals without metabolic acidosis was not evident from these
studies. In earlier studies,15 we propose that systemic Hþ
retention ensues when GFR falls in subjects ingesting an Hþ -
inducing diet such that the overall kidney Hþ excretion
temporarily falls below intake. Hþ retention increases until
the kidney completes necessary adjustments to increase per
nephron Hþ excretion in the remaining functioning ne-
phrons, but this adjustment does not completely correct Hþ
retention that is sustained as long as dietary Hþ intake is not
reduced. Supporting this hypothesis, Hþ retention induced by
dietary Hþ is chronically maintained with normal plasma
acid–base parameters in animals with intact nephron mass as
long as dietary Hþ intake continues and resolves only after the
increment in dietary Hþ is discontinued.19 We further
propose that Hþ retention increases kidney AII, ET-1, and
Aldo levels that augment distal nephron acidification as
shown, similar to augmented distal nephron acidification in
animals with intact nephron mass in response to an increment
in dietary Hþ .23,27 We propose that Hþ retention persists in
animals with reduced GFR as long as they ingest standard Hþ -
inducing, casein-based, animal chow and in humans eating the
Hþ -inducing diets typical of industrialized societies.25 Redu-
cing Hþ retention of 2/3 Nx animals to Sham levels with
dietary alkali lowered plasma and kidney levels of AII, ET-1,
and Aldo, as well as lowered augmented distal nephron
acidification. As AII, ET, and mineralocorticoid antagonists
lowered distal nephron acidification in 2/3 Nx animals without
affecting higher Hþ retention, the data support the hypothesis
that Hþ retention increases AII, ET, and Aldo activities, which
in turn augment distal nephron acidification.
Table 5 shows that microdialysate net Hþ addition in 2/3
Nx animals given valsartan that reduced distal nephron JHCO3
was not different from 2/3 Nx animals not given valsartan.
Instead, valsartan-treated 2/3 Nx animals had lower plasma
pH, PCO2, and TCO2, that is, they had metabolic acidosis. We
hypothesize that the overall system for protection against an
Hþ challenge is designed to preserve extracellular fluid (ECF)
acid–base parameters as a first priority, particularly ECF pH,
as speculated by others.28 Consequently, we hypothesize that
the described retained Hþ in response to a decrease in GFR
first titrates ECF and mostly intracellular fluid buffers,29 and
induces distal nephron acidification through the mechanisms
discussed. We hypothesize that there is a limit to the level of
Hþ retention, beyond which reduced kidney Hþ excretion
and/or further Hþ addition ultimately compromises ECF
acid–base parameters, yielding metabolic acidosis. We spec-
ulate that the level of Hþ retention in the 2/3 Nx animals is
near this limit such that reduced distal nephron acidification
induced by valsartan did not further increase Hþ retention
but instead induced metabolic acidosis with or without
titration of other sources of buffer such as bone.
The mechanism(s) by which Hþ retention associated with
reduced GFR increases kidney AII, ET-1, and Aldo levels are
unclear. Dietary Hþ increases kidney AII and its receptor
expression acutely and chronically.20 An acid extracellular
environment increases ET-1 release from kidney microvas-
cular endothelial cells in vitro,30 possibly contributing to
increased levels in the kidney. Nevertheless, kidney epithelial
cells make and secrete ET-131 and might also be a source of
the augmented kidney ET-1. In addition, increasing perfusate
acidity augments Aldo secretion from isolated perfused
adrenal glands,32 and Hþ -inducing dietary protein23,33 and
NH4Cl
34 increase plasma Aldo in rats and humans,
respectively. Additional studies will be necessary to determine
precisely how Hþ retention associated with reduced GFR
increases kidney AII, ET-1, and Aldo levels.
Although AII, ET, and mineralocorticoid receptor antag-
onism each reduce distal nephron acidification in 2/3 Nx
animals, these studies support a quantitatively greater
contribution of AII compared with the remaining substances
in mediating increased distal nephron acidification in Nx
compared with Sham animals. For example, net JHCO3 was no
different in Nx compared with Sham animals when each
received the AII receptor antagonist but was higher in Nx
compared with Sham when each group was given the ET or
mineralocorticoid receptor antagonists individually. The ET
and mineralocorticoid receptor antagonist also reduced net
JHCO3 but, as mentioned, quantitatively less so than did the
AII antagonist. Table 5 shows that Nx animals given the AII
antagonist had lower plasma levels and kidney microdialysate
addition of ET-1 and Aldo, consistent with AII-mediated
increases in ET-1 and Aldo levels in Nx animals. Other
investigators report that AII increases kidney levels of ET-121
and Aldo.22 Consequently, AII might exert its quantitatively
greater increase in JHCO3 by stimulating distal nephron H
þ
transporters directly and/or through increasing ET-1 and
Aldo levels that, respectively, stimulate Naþ /Hþ exchange
and Hþ -ATPase activity.23 In addition, increased kidney
ET-1 levels associated with Nx12 might increase kidney Aldo
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levels,35 similar to mechanisms that mediate increased distal
nephron acidification in animals with intact nephron mass in
response to dietary Hþ .23
As AII might exert its effect on distal nephron
acidification through different ‘downstream’ pathways, AII
antagonists might have different quantitative effects on these
AII-induced pathways. For example, AII reduces kidney
cAMP36 and reduced cAMP lowers distal nephron HCO3
secretion.37 Consequently, AII antagonists might lead to
increased HCO3 secretion, which is an additional mechan-
ism for decreased net JHCO3 rather than, or in combination
with, decreased Hþ secretion. These varied effects on down-
stream pathways might also apply to ET and Aldo antagonists.
Our techniques did not distinguish how these receptor
antagonists affect downstream pathways, allowing for possibly
other interpretations of the distal nephron acidification data.
These studies support the hypothesis that the augmented
distal nephron acidification of 2/3 Nx animals compared with
Sham animals is due to enhanced distal nephron Naþ /Hþ ,
Hþ -ATPase, and Hþ , Kþ -ATPase activity. Previous studies
did not support a contribution of Hþ , Kþ -ATPase in the
augmented distal nephron acidification of 5/6 Nx animals,12
and thus the physiological significance of this finding is not
clear and deserves further elucidation. The data support
the hypothesis that AII, ET, and Aldo contribute to the
enhanced Naþ /Hþ and Hþ -ATPase activity, but we found
no support for any of these substances individually enhan-
cing Hþ , Kþ -ATPase activity. In addition, Hþ , Kþ -ATPase
activity was lower in Nx animals given dietary alkali
(NxþCaHCO3) to reduce Hþ retention to Sham levels
than in those given no Caþ þ salt and those given CaGlu
(NxþCaGlu). Among possible explanations, dietary alkali
such as CaHCO3 might lower H
þ , Kþ -ATPase activity in 2/3
Nx animals through mechanisms not revealed in this study.
Alternatively, the minimum electrolyte diet might have
increased Hþ , Kþ -ATPase activity in Nx animals, which was
reduced by dietary alkali. In any case, these studies support the
hypothesis that enhanced Naþ /Hþ exchange and enhanced
Hþ -ATPase activity mediate the largest component of the
augmented distal nephron acidification of 2/3 Nx animals.
The increased distal nephron acidification shown in these
studies presumably helps 2/3 Nx animals avoid metabolic
acidosis. Animals with 2/3 Nx have reduced but better-
preserved GFR than the classic 5/6 Nx animals, yet are
characterized by a chronic state of Hþ retention and high
levels of AII, ET-1, and Aldo, despite their plasma acid–base
parameters being comparable to those of Sham animals.
These data suggest physiological and possibly clinical
implications for 2/3 Nx animals and humans with GFR that
is reduced, but not to levels low enough to cause metabolic
acidosis. Such patients are of particular importance, con-
sidering that they also appear to have acid retention.8
Chronic Hþ retention might yield untoward consequences
beyond increasing levels of these three substances, each of
which contribute to progressive nephropathy,13,15,18,38 and
supports the use of their receptor antagonists as kidney
protective agents. On the other hand, as these substances
contribute physiologically to increase distal nephron acid-
ification that helps maintain normal plasma acid–base
parameters in the setting of reduced GFR, these antagonists
might inhibit acidification and thereby induce metabolic
acidosis when used as kidney protective agents in patients
with reduced GFR. In support of this concern, Nx animals
given the AII receptor antagonist had lower pH, plasma
TCO2, and PCO2 than baseline Nx animals, similar to lower
plasma TCO2 in humans consuming dietary acid, who
received an AII receptor antagonist.39 In addition, Nx
animals had lower urine NH4
þ excretion when given the
AII receptor antagonist, consistent with AII-induced kidney
NH4
þ production.26 Dietary alkali sufficient to restore Nx
Hþ retention to Sham levels ameliorates GFR decline in 2/3
Nx animals14,15 and lowers plasma and kidney AII, ET-1, and
Aldo to levels not different from Sham. By contrast, 2/3 Nx
animals given AII antagonist have persistent Hþ retention
and high plasma and kidney levels of AII (Table 5), factors
that might contribute to progressive GFR decline in patients
with reduced GFR despite kidney protective strategies such as
blood pressure reduction and anti-AII therapy.16 Together,
these data support an important role of Hþ retention in the
augmented distal nephron acidification and inducing high
AII, ET-1, and Aldo levels associated with 2/3 Nx animals.
The data additionally support dietary alkali as a more
physiological kidney-protective strategy than receptor an-
tagonists in subjects with reduced GFR.
In summary, 2/3 Nx animals without metabolic acidosis
nevertheless have increased distal nephron acidification that
is induced by Hþ retention, maintained through AII, ET, and
mineralocorticoid receptors, and is associated with high
levels of AII, ET-1, and Aldo in the kidney. Dietary alkali
reduces Hþ retention with subsequent reduction of the
augmented distal nephron acidification in Nx, along with
reductions of plasma and kidney levels of AII, ET-1, and
Aldo. The data support the hypothesis that Hþ retention in
2/3 Nx animals augments distal nephron acidification
predominantly through increased AII, ET, and Aldo activity,
but AII has the greatest quantitative effect. As 2/3 Nx appears
to model patients with GFR that is reduced but not to a level
that causes metabolic acidosis, these mechanisms might
account for the apparent increase in per nephron acidifica-
tion observed in human subjects with reduced GFR and
might contribute to their observed progressive nephropathy.
MATERIALS AND METHODS
Animals, diet, and protocol
Eight-week-old male and female Munich-Wistar rats (Harlan
Sprague–Dawley, Houston, TX) were fed a custom minimum
electrolyte diet with 20% protein as purified high-nitrogen casein
(ICN Nutritional Biochemicals, Cleveland, OH) 1 week before
kidney mass–reduction surgery (see below). Casein is the standard
protein in rat chow and is acid-inducing when ingested.13 In
preliminary studies, Nx and Sham animals were fed 18.6±0.9 vs.
20.9±0.7 g per day, respectively (n¼ 4, P¼ 0.09), and thus all
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animals received 18 g per day to assure identical diet intake. As AT 1
receptor antagonism with losartan reduced AII-induced ET-1 in
glomerular arteries in partially nephrectomized rats40 and valsartan
has greater affinity for the AT 1 receptor,41 some animals received
valsartan (Novartis Pharmaceuticals, East Hanover, NJ), mixed with
their diet at a dose of 10mg/kg body weight (bw)/day, a dose that
reduced AII-induced Aldo synthase mRNA in rats.42 In studies
attempting to determine the maximum inhibitory dose of valsartan
on distal nephron JHCO3, animals given doses as high as 25mg/kg
were hemodynamically unstable under anesthesia when this
valsartan dose was combined with the other two antagonists as
dictated by one arm of the protocol (see below). These animals were
nevertheless hemodynamically stable when the 25mg/kg bw/day
dose was given alone, without the other antagonists. Distal nephron
JHCO3 was not different in animals given the 25 compared with
10mg/kg bw/day dose (10.6±0.7 vs. 11.2±0.5 pmol/mmmin,
respectively, n¼ 4 animals each, P¼ 0.24), supporting the hypoth-
esis that the 10mg/kg bw/day dose used in these studies yielded
maximum inhibitory effect on distal nephron JHCO3. Other animals
received bosentan (Hoffmann-LaRoche, Basel, Switzerland), a non-
peptide ETA/B receptor antagonist,43 mixed with their diet at a dose
of 100mg/kg bw/day. This oral dose blocks the action of pressor
doses of intravenous big ET-1 for more than 24 h.43 Previous studies
determined that 100mg/kg bw/day bosentan was maximally
inhibitory on distal nephron JHCO3 without inducing hemodynamic
instability under anesthesia.12 Still other animals received epler-
enone (Pfizer, New York, NY) in their diet at a dose of 100mg/kg
bw/day, an oral dose that reversed kidney fibrosis in the
deoxycorticosterone/salt rat.44 In studies attempting to determine
the maximum inhibitory dose of eplerenone on distal nephron
JHCO3, animals given doses as high as 300mg/kg were hemodyna-
mically unstable under anesthesia when this eplerenone dose was
combined with the other two antagonists as dictated by the protocol
(see below). These animals were nevertheless hemodynamically
stable when the 300mg/kg bw/day eplerenone dose was given alone,
without the other antagonists. Distal nephron JHCO3 was not
different in animals given the 300 compared with 100mg/kg bw/day
eplerenone dose (22.6±1.0 vs. 23.6±0.9 pmol/mmmin, respec-
tively, n¼ 4 animals each, P¼ 0.20), supporting the hypothesis that
the 100mg/kg bw/day dose used in these studies yielded maximum
inhibitory effect on distal nephron JHCO3. One animal group
received all three receptor antagonists and all antagonists were
mixed with the ingested chow. As dietary alkali such as CaHCO3
reduces Hþ retention without increasing blood pressure,13 some
animals received dietary CaHCO3 sufficient to reduce H
þ retention
to Sham levels to examine its effect on distal nephron JHCO3 and on
kidney AII, ET-1, and Aldo levels. Nx animals fed diets with
125mmol/l/g diet/day of added Ca2(HCO3)2 had no net H
þ
addition compared with Sham animals,14,15 and thus Nx animals
received this amount. Nx animals fed 125 mmol/l/g diet/day of Ca2þ
gluconate were included to control for dietary Ca2þ .13–15
Kidney mass reduction
Nx was performed by surgical removal of approximately 2/3 of
kidney mass in two stages, and chronic carotid and jugular venous
lines inserted.14,15 Animals were studied 4 weeks after the second of
the two-stage kidney mass–reduction surgery.
Arterial blood parameters
We measured pH, PCO2 (IRMA Blood Analysis System, Diametrics
Medical, St Paul, MN), TCO2 by ultrafluorometry (see below), and
electrolytes, AII, ET-1, and Aldo in 0.35ml of blood from a chronic
carotid arterial catheter at weeks 1 and 3 after kidney mass–reduc-
tion surgery in eight each of awake, comfortably restrained, and
calm animals. An equivalent amount of blood from identically
treated animals was replaced through a chronic jugular venous
catheter.
Urine NAE
We measured 24-h urine NAE45 in a sample collected 28 days (week 4)
after surgery in eight animals from each of the groups kept in
metabolic cages.
GFR measurement
GFR was measured at 3 weeks in conscious animals by slope of the
decline in plasma concentration of intravenously infused 3H-inulin
over 180min46 as described.14,15
Microdialysis to compare kidney cortical Hþ , AII, ET-1, and
Aldo
Immediately after GFR measurement (3 weeks after the second
surgery), Nx and Sham animals underwent surgery to insert a
microdialysis catheter in their kidney cortex through a flank incision.27
One week later (4 weeks after surgery), microdialysis was performed in
comfortably restrained, conscious, and calm animals. The micro-
dialysate was designed to have no net change in microdialysate Hþ
content ([Hþ ] in collected microdialysate minus [Hþ ] in infused
microdialysate times collected microdialysate volume) when perfused
in Sham.14,15,27 The technique assumes that greater-than-Sham Hþ
content in the kidney cortex (free Hþ þHþ bound to buffers) will be
reflected by net Hþ addition to microdialyste and lower-than-Sham
Hþ content by net removal of Hþ from the infused microdialysate.
Greater microdialysate Hþ addition in one group compared with
another was assumed to indicate greater Hþ retention and vice
versa.14,15,27 Relative kidney cortical AII, ET-1, and Aldo contents were
determined by measuring addition of these substances from kidney
parenchyma to microdialysate.
Micropuncture protocol
Five to six weeks after Nx and Sham surgery, animals were
anesthetized with Inactin and prepared for micropuncture of
accessible distal tubules.47 In situ early distal flow rate of Nx and
Sham was 8.8±0.6 (n¼ 6) and 5.7±0.4 nl/min (n¼ 8), respectively.
Distinct superficial distal nephrons were perfused at 9 or 6 nl/min to
approximate in situ flow rates. Diet but not H2O was withheld the
evening before micropuncture to yield higher baseline HCO3
reabsorption48 as described.47 Perfusate was as follows (in mmol/l):
Naþ 61, Kþ 4, Cl 40, HCO3 5, gluconate 20, and raffinose 200. It
had 5mmol/l HCO3 and 40mmol/l Cl
 to approximate early distal
nephron concentrations in situ,49 contained raffinose to minimize
fluid transport, and gluconate substituted for Cl.47
Identification of Hþ transport mediators of changes in distal
nephron JHCO3
We compared net decrease in distal nephron JHCO3 in response to
Hþ transport inhibitors in Nx and Sham animals to assess the
contribution of Naþ /Hþ exchange (EIPA, 105mol/l), Hþ -ATPase
(bafilomycin, 107mol/l), and Hþ ,Kþ -ATPase (Schering 28080,
105mol/l) as described.23 Greater inhibitor-induced decrease in
JHCO3 in Nx compared with Sham animals determined increased
activity of the Hþ -transporter inhibited by that agent.23
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Analytical methods
Collected and infused dialysate, arterial plasma, and microdialysate
were immediately analyzed for TCO2 with flow-through ultrafluoro-
metry.50 Dialysate and plasma AII were measured with a radio-
immunoassay kit (SPI-BIO, Artigues, France) after storage at 80 1C
in tubes containing EDTA, Pepstatin, enalaprilate, and 1, 10
phenanthroline, and evaporated to dryness as described.51 Dialysate
and plasma ET-1 were measured as described previously27 with a
radioimmunoassay kit (Peninsula Laboratories, Belmont, CA) after
extraction using Bound Elut C18 columns (Varian, Harbor City,
CA). Dialysate and plasma Aldo were measured after extraction with
Bound Elut C18 columns (Varian) using a radioimmunoassay kit
(Diagnostic Products, Los Angeles, CA).15
Calculations
Net dialysate Hþ addition was calculated as described.19 Positive
values for net Hþ addition indicated greater Hþ content in
collected compared with infused dialysate (i.e., Hþ gain) and
negative values indicated lower Hþ content (i.e., Hþ loss). Net Hþ
addition for each of three collection periods was averaged for a
single animal value and averaged for each animal for a group value.
Distal nephron net TCO2 reabsorption was equated to net HCO3
reabsorption, calculated as the difference between the infused and
collected amounts as described.47
Statistical analysis
Data were expressed as means±s.d. The differences among the
multiple groups were considered with one-way analysis of variance
followed by post-hoc Tukey’s test. A P-value of less than 0.05
indicates a statistical significance. Analyses were performed in SPSS
18 (Chicago, IL) and graphs were created using R 2.13.1 (R Core
Development Team, 2011).
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